Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

30 Nov 2020

Abstract excerpt

Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33257686
DOI: 10.1038/s41467-020-19819-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platformPMID 33257686Read ↗

Development of a Synthetic Poxvirus-Based SARS-CoV-2 VaccineSemantic proximity Read ↗

Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus PlatformSemantic proximity Read ↗

Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo ApproachSemantic proximity Read ↗

Rapid development of a synthetic DNA vaccine for COVID-19Semantic proximity Read ↗

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccinationSemantic proximity Read ↗

Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adultsSemantic proximity Read ↗

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read ↗

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variantsSemantic proximity Read ↗

The Evolution of Poxvirus VaccinesSemantic proximity Read ↗

Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in miceSemantic proximity Read ↗

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2Semantic proximity Read ↗

MVA and NYVAC as Vaccines against Emergent Infectious Diseases and CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.